Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

Right Ventricular Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis

Gianluca Paternoster, MD, PhD*, Pietro Bertini, MD, PhD†, Pasquale Innelli, MD‡, Paolo Trambaiolo, MD, PhD†, Giovanni Landoni, MD†, Federico Franchi, MD, PhD§, Sabino Scolletta, MD§, Fabio Guarracino, MD†

*Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy
†Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
‡Intensive Coronary Care Unit, Division of Cardiology, San Carlo Hospital, Potenza, Italy
§Intensive Coronary Care Unit, Sandro Pertini Hospital, Roma, Italy
||Department of Anesthesiology and Intensive Care, Istituto di Ricerca a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
§Department of Medicine, Surgery and Neuroscience, Anesthesia and Intensive Care Unit, University of Siena, Siena, Italy

Objective: This systematic review and meta-analysis aimed to describe the features of right ventricular impairment and pulmonary hypertension in coronavirus disease (COVID-19) and assess their effect on mortality.

Design: The authors carried out a systematic review and meta-analysis of observational studies.

Setting: The authors performed a search through PubMed, the International Clinical Trials Registry Platform, and the Cochrane Library for studies reporting right ventricular dysfunction in patients with COVID-19 and outcomes.

Participants: The search yielded nine studies in which the appropriate data were available.

Interventions: Pooled odds ratios were calculated according to the random-effects model.

Measurements and Main Results: Overall, 1,450 patients were analyzed, and half of them were invasively ventilated. Primary outcome was mortality at the longest follow-up available. Mortality was 48.5% versus 24.7% in patients with or without right ventricular impairment (n = 7; OR = 3.10; 95% confidence interval [CI] 1.72-5.58; p = 0.0002), 56.3% versus 30.6% in patients with or without right ventricular dilatation (n = 6; OR = 2.43; 95% CI 1.41-4.18; p = 0.001), and 52.9% versus 14.8% in patients with or without pulmonary hypertension (n = 3; OR = 5.75; 95% CI 2.67-12.38; p < 0.001).

Conclusion: Mortality in patients with COVID-19 requiring respiratory support and with a diagnosis of right ventricular dysfunction, dilatation, or pulmonary hypertension is high. Future studies should highlight the mechanisms of right ventricular derangement in COVID-19, and early detection of right ventricular impairment using ultrasound might be important to individualize therapies and improve outcomes.

© 2021 Elsevier Inc. All rights reserved.

Key Words: right ventricle; meta-analysis; COVID-19; ARDS; echocardiography; critical care

IN DECEMBER 2019, an outbreak of pneumonia emerged in Wuhan (Hubei Province, China) and quickly was discovered to be caused by a new coronavirus, later called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes coronavirus disease (COVID-19). Since then, the virus has spread rapidly to other provinces in mainland China and, so far, more than 200 countries. It was recognized as a
pandemic by the World Health Organization (WHO) in March 2020.1,2 The main clinical feature of the infection involves the respiratory system, further declining respiratory insufficiency with the need for supportive therapy with high-flow oxygen or non-invasive mechanical ventilation. Eventually, acute respiratory distress syndrome (ARDS) can develop, requiring invasive ventilation, prone positioning, and, in severe cases, venovenous extracorporeal oxygenation (VV-ECMO).3

Respiratory failure in patients with COVID-19 presents as a combination of two processes: viral pneumonia and ARDS. These conditions can cause diffuse alveolar damage with hyaline membrane formation followed by interstitial widening, edema, and fibrosis due to inflammation and proliferative disease.4

Another finding in COVID-19–related ARDS is pulmonary thrombosis that might involve pulmonary microvessels, suggesting thrombotic microangiopathy and causing pulmonary hypertension (PH), which likely increase mortality:5,6 This disorder could explain unexpected manifestations such as dilated pulmonary vessels and right ventricular dysfunction.7 In patients with COVID-19–related ARDS, pulmonary hypertension also might be due to the involvement of angiotensin converting enzyme (ACE) 2 receptors and the effects of chemokines and cytokines.8 Notably, cardiac failure, in particular right ventricle (RV) dysfunction, commonly is encountered in moderate-to-severe non-COVID-19 ARDS and is reported to be one of the major determinants of mortality.9

The aim of this systematic review and meta-analysis was to determine if echocardiographic evidence of RV dysfunction, echocardiographic evidence of RV dilation, and/or pulmonary hypertension are associated with mortality in patients with COVID-19.

Methods

The authors adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses10 to conduct and report this systematic review. The protocol was registered to the PROSPERO database with ID CRD42020216221.

Literature Search, Study Selection, and Outcomes

The authors performed a thorough literature search in PubMed, Cochrane Library, and the International Clinical Trials Registry Platform databases through October 23, 2020 to identify published or ongoing studies on the subject. The keywords used were (“COVID-19” OR “SARS-CoV-2” OR “Coronavirus”) AND (“right ventricle” OR “right heart” OR “echocardiography” OR “pulmonary hypertension” OR “pulmonary pressure”). The authors manually recorded the reference list of all significant publications. Inclusion criteria were as follows: all types of studies, studies investigating right ventricular function or pulmonary pressure assessment using echocardiography, studies in adult patients with COVID-19, and studies reporting mortality data. The authors excluded studies involving patients <18 years old, case reports or case series, and narrative or systematic reviews. Titles and abstracts subsequently were screened by two reviewers (G.P. and P.B.) to recognize possibly relevant articles. Discrepancy in judgment was resolved after discussion. The retrieved full manuscripts were reviewed for relevancy and presence of outcomes of interest, and the list of studies to be included in the quantitative analysis was generated.

Data Synthesis and Statistical Analysis

The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized controlled trials. The methodologic power of observational studies was evaluated by the Newcastle–Ottawa Scale (NOS).11 The NOS was designed to judge a study from three perspectives: the study’s selection, the comparability, and the determination of outcomes. Favorable judgment was made by awarding a star. Nine stars indicated the highest strength, and six or more stars designated elevated quality.

A meta-analysis was performed when outcomes were reported in at least two studies. Odds ratios (ORs) and 95% confidence intervals were estimated. Metric I² was used to assess heterogeneity among studies independently of the number of studies.12 The random-effects model was used to calculate OR. Two-tailed p values with p < 0.05 were judged as statistically significant. Publication bias was assessed by visually inspecting the funnel plot when more than ten studies were found. Funnel plot asymmetry was detected using Egger’s regression test.13 All data from the included studies were extracted into the Review Manager (RevMan) software, version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) for macOS.

RV dysfunction was assessed by at least one or a combination of the following: fractional area change (FAC) < 35%, tissue Doppler-derived imaging (TDI) tricuspid lateral annular systolic velocity wave (S’) < 9.5 cm/s, tricuspid annular plane systolic excursion (TAPSE) < 17 mm, and RV index of myocardial performance (RIMP) by TDI > 0.43, as recommended by the guidelines.14 A diameter >41 mm at the base and >35 mm at the midlevel in the RV-focused view were used to identify RV dilatation.14 PH was diagnosed by mean pulmonary arterial pressure (PAPm) > 25 mmHg, as recommended in the guidelines.15

Results

Search Results

A list of 312 studies was identified through the literature search, among which 60 were duplicates, and 200 were excluded after an initial review of titles and abstracts. The remaining 28 full-text publications were reviewed and screened for inclusion criteria (Supplement Table 1). Finally, nine were selected for systematic review and meta-analysis.16-24 The search and selection process is depicted in the Preferred Reporting Items for Systematic Review and Meta-Analyses flow diagram in Figure 1.
Study and Patient Characteristics

Approximately half of the patients were invasively ventilated. Study details and patient characteristics are reported in Table 1 and Table 2. The nine studies included in the analysis were all observational investigations conducted in 2020.

Of the selected studies, seven evaluated the influence of RV dysfunction on mortality and included 866 patients. There was a significant increase in mortality in patients with RV dysfunction when compared with patients without RV dysfunction (121/215 [48.5%] vs 199/651 [24.7%]; number of studies = seven; OR = 3.10; 95% CI 1.72-5.58; p for effect = 0.0002; p for heterogeneity = 0.001; I² = 63.0%).

Of the selected studies, six evaluated the influence of RV dilatation on mortality and included 1,102 patients. There was a significant increase in mortality in patients with RV dilatation when compared with patients without RV dysfunction (145/299 [56.3%] vs 198/803 [30.6%]; n = 6; OR = 2.43; 95% CI 1.41-4.18; p for effect = 0.001; p for heterogeneity = 0.005; I² = 55.0%).

Only three studies reported data on PH for a total of 446 patients. Mortality was 72 of 136 (52.9%) versus 46 of 310 (14.8%) in patients with and without PH (n = 3; OR = 5.75; 95% CI 2.67-12.38; p for effect < 0.001; p for heterogeneity = 0.001; I² = 55.0%).

| Study Characteristics                                      | Author          | Region | Study Design                        | No. of patients |
|------------------------------------------------------------|-----------------|--------|-------------------------------------|-----------------|
| Argulian E. 2020                                           | USA             | Retrospective | 137                              |
| Garcia-Cruz E. 2020                                        | Mexico          | Multicenter, Cross-sectional, Observational | 82               |
| Jain S.S. 2020                                             | USA             | Retrospective, Observational | 72               |
| Kim J. 2020                                                | USA             | Multicenter, Retrospective, Observational | 510              |
| Li Y. 2020                                                 | China           | Prospective, Observational | 120              |
| Mahmoud-Elsayed H. 2020                                    | UK              | Retrospective, Observational, Cohort | 74               |
| Moody W. 2020                                              | UK              | Multicenter, Retrospective, Observational | 164              |
| Pagnesi M. 2020                                            | Italy           | Single Center, Observational, Cross-sectional | 200              |
| Rath D. 2020                                               | Germany         | Prospective, Observational | 123              |
heterogeneity = 0.18; I² = 41%). Forest plots of the pooled results are shown in Figure 2 (panels A-C).

Risk of Bias in Included Studies

The nine included studies were of high quality according to the NOS assessment tool for cohort studies, and the risk of bias was evaluated as detailed in Supplemental Table 2.

Discussion

To the authors’ knowledge, this was the first systematic review and meta-analysis assessing the effects of RV dysfunction or dilatation in adult patients with COVID-19. The authors found a significantly increased mortality in patients with RV dysfunction and in those with RV dilatation and/or PH compared to other patients with COVID-19 without acute right ventricular alterations. RV dysfunction in patients with ARDS is a well-known finding; however, the authors decided to perform the present meta-analysis after increasing evidence of a strong relationship between RV failure and mortality in patients with COVID-19 was suggested in several studies.25-28

In the present meta-analysis, the authors included nine observational studies, which met the inclusion criteria, to evaluate the impact of right ventricular alteration on outcome in adult patients with COVID-19. The authors found a significantly increased mortality in patients with RV dysfunction and in those with RV dilatation and/or PH compared to other patients with COVID-19 without acute right ventricular alterations.

Table 2

| Author               | Age, y | Male | ICU   | NIV | MV | RV Dilatation | RV Impairment | Mortality |
|----------------------|--------|------|-------|-----|----|---------------|---------------|-----------|
| Argulian E.          | 66 ± 14.6 | 58.1% | NA    | NA  | NA | 31.0%         | NA            | 20.0%     |
| Garcia-Cruz E.       | 56 (50-66) | 62.2% | NA    | NA  | NA | 28.0%         | NA            | 46.0%     |
| Jain S.S.            | 61 (50.8-70.3) | 72.2% | NA    | NA  | NA | 15.3%         | 51.7%         | 33.3%     |
| Kim J.               | 64 ± 14  | 65.5% | 67.6% | 43.0%| 60.3%|            |               |           |
| Li Y.                | 61 ± 14  | 47.5% | 21%   | 5%  | 12.5%|            |               |           |
| Mahmoud-Elsayed H.   | 59 ± 13  | 78.4% | NA    | NA  | NA | 41.0%         | 27.0%         | 37.8%     |
| Moody W.             | 61 ± 13  | 77.4% | NA    | NA  | NA | 38.0%         | 35.3%         | 37.0%     |
| Pagnesi M.           | 62 (55-74) | 65.5% | 3.5%  | NA  | 3.5%| 14.5%         | NA            | 12.5%     |
| Rath D.              | 68 ± 15  | 62.6% | 45.5% | NA  | 39.8%| 48.9%         | 13.7%         | 13.0%     |

Abbreviations: ICU, intensive care unit; MV: mechanical ventilation; NIV, noninvasive ventilation; NA: not available; RV: right ventricle; Age is indicated as mean and SD or as median and IQR (numbers in parentheses).

Fig 2. (A) Forest plot depicting analysis of the odds of mortality from acute respiratory distress syndrome (ARDS) in patients with coronavirus disease (COVID-19) with right ventricular dilatation. (B) Forest plot depicting analysis of the odds of mortality from ARDS in patients with COVID-19 with right ventricular dysfunction. (C) Forest plot depicting analysis of the odds of mortality from ARDS in patients with COVID-19 with pulmonary hypertension. PH, pulmonary hypertension.
patients with COVID-19. A recent survey on cardiac involvement in COVID-19 showed that the left ventricle was affected in 32% of patients, right ventricle in 42%, and both sides were involved in 21% of patients. Interestingly, only in 5% of patients was no cardiac involvement reported.29 Heart failure, particularly RV dysfunction, commonly is encountered in moderate-to-severe ARDS and is reported to be one significant determinant of mortality.30

The negative influence of high-pressure mechanical ventilation on hemodynamics has been recognized,31 as the inevitable rise in intrathoracic pressure caused by positive-pressure ventilation, or positive end-expiratory pressure (PEEP), is associated with a decrease in CO, probably mediated by impairment of venous return.32

RV dilatation, in response to an increase in afterload, raises the right ventricular distending pressure, which can reduce the pressure gradient for the subendocardial coronary blood flow with a corresponding reduction in right ventricular contractility.33

Along with alveolar damage, ARDS directly causes injury to the pulmonary circulation through several pathophysiologic mechanisms: hypoxic pulmonary vasoconstriction, release of vasoconstrictive mediators, extrinsic vascular compression by interstitial edema, and blood vessel remodeling. All of these factors contribute to PH, elevated pulmonary vascular resistance, increased right ventricular afterload and, eventually, RV failure. RV dysfunction is a common and often primary cause of cardiovascular insufficiency in the critically ill.34

The pulmonary vascular bed is more sensitive to the vasoconstrictive influence of respiratory acidosis. Moreover, pulmonary vascular dysfunction might be associated with ARDS, leading to increased right ventricular afterload and, eventually, RV dysfunction.

In patients with COVID-19, a cytokine storm is common. Interleukin 6 (IL-6) serum concentration correlates with respiratory dysfunction, ARDS, and poor clinical outcomes. In addition, SARS-CoV-2 direct injury to the RV is expected to increase the release of vasoactive peptides and promote myocardial recruitment of inflammatory cells. Cardiac myofibroblasts and cardiomyocytes act as key sources for a wide array of pro-inflammatory cytokines, including IL-6, and are highly responsive to IL-6, IL-1β, and TNFα. Furthermore, prolonged/excessive synthesis of IL-6 is reported to induce cardiac hypertrophy, fibrosis, and diastolic dysfunction. The proinflammatory cytokine cascade can contribute to RV dysfunction through negative inotropic effects on the myocardium. Taken together, depressed RV contractility may prove to be fatal in the face of acutely elevated pulmonary vascular resistance from ARDS and pulmonary embolism in COVID-19.35

As demonstrated by this meta-analysis, the impact of right ventricle dysfunction on COVID-19 mortality highlighted the importance of echocardiographic screening in such patients throughout the clinical course, even if protective or noninvasive ventilation approaches are used.36

**Study Limitations**

All studies included in the present metaanalysis were observational. In addition, clinical setting and ventilation protocols varied in different studies, and this should be considered. Moreover, echocardiographic RV assessment might not be homogeneous across the studies included in the meta-analysis.

**Conclusions**

Alterations in RV function or PH dimensions in patients with COVID-19 undergoing respiratory support seem to play a major role in determining mortality rate. Thrombotic events, hypoxemic vasoconstriction, cytokine release, and direct viral damage all are possible contributors to RV derangement. The present analysis reinforced the need for a broader implementation of screening patients with COVID-19 for RV derangement, and a focused ultrasound assessment might be important in patients presenting with COVID-19 needing respiratory support.

**Acknowledgements**

We thank Dr. Daniel Manzur Sandoval and Dr. William Moody and their colleagues for sharing their data.

**Conflict of interest**

None.

**Supplementary materials**

Supplementary material associated with this article can be found in the online version at doi:10.1053/j.jvca.2021.04.008.

**References**

1 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–4.
2 Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ 2020;368:m1036.
3 Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020;396:1071–8.
4 Maiiese A, Manetti AC, La Russa R, et al. Autopsy findings in COVID-19-related deaths: A literature review [Epub ahead of print]. Forensic Sci Med Pathol 2020, https://doi.org/10.1007/s12024-020-00310-8.
5 Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020;22:95–7.
6 De Cobelli F, Pumabo D, Ciceri F, et al. Pulmonary vascular thrombosis in COVID-19 pneumonia [Epub ahead of print]. J Cardiothorac Vasc Anesth 2021. https://doi.org/10.1053/j.jvca.2021.01.011.
7 Lazzeri C, Bonizzi M, Batacchi S, et al. Echocardiographic assessment of the right ventricle in COVID-related acute respiratory syndrome. Intern Emerg Med 2021;16:1–5.
8 Revercomb L, Hanmandlu A, Wareing N, et al. Mechanisms of pulmonary hypertension in acute respiratory distress syndrome (ARDS). Front Mol Biosci 2020;7:624093.

9 Zochios V, Parhar K, Tunnicliffe W, et al. The right ventricle in ARDS. Chest 2017;152:181–93.

10 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 2009;6:e1000100.

11 GA Wells, B Shea, D O’Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Retrieved from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed March 2, 2021.

12 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

13 Song F, Khan KS, Dinnes J, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002;31:88–95.

14 Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28;1-39.e14.

15 Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016;69:177.

16 Li Y, Li H, Zhu S, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc Imaging 2020;13:2287–99.

17 Kim J, Volodarskiy A, Sultana R, et al. Prognostic utility of right ventricular remodeling over conventional risk stratification in patients with COVID-19. J Am Coll Cardiol 2020;76:1965–77.

18 Mahmoud-Elsayed HM, Moody WE, Bradlow WM, et al. Echocardiographic findings in patients with COVID-19 pneumonia. Can J Cardiol 2020;36:1201–7.

19 Moody WE, Mahmoud-Elsayed HM, Senior J, et al. Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19 according to race. CJC Open 2021;3:91–100.

20 Rath D, Petersen-Uribe A, Avdú A, et al. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. Clin Res Cardiol 2020;109:1491–9.

21 Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart 2020;106:1324–31.

22 Argulian E, Sud K, Vogel B, et al. Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC Cardiovasc Imaging 2020;13:2459–61.

23 Jain SS, Liu Q, Raikhelkar J, et al. Indications for and findings on transthoracic echocardiography in COVID-19. J Am Soc Echocardiogr 2020;33:1278–84.

24 García-Cruz E, Manzur-Sandoval D, Rascón-Sabido R, et al. Critical care ultrasonography during COVID-19 pandemic: The ORACLE protocol. Echocardiography 2020;37:1533–61.

25 Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol 2020;76:2043–55.

26 D’Alto M, Marra AM, Severino S, et al. Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Crit Care 2020;24:670.

27 Szekely Y, Lichter Y, Taieb P, et al. Spectrum of cardiac manifestations in COVID-19: A systematic echocardiographic study. Circulation 2020;142:342–53.

28 D’Andrea A, Scarafile R, Riegler L, et al. Right ventricular function and pulmonary pressures as independent predictors of survival in patients with COVID-19 pneumonia. JACC Cardiovasc Imaging 2020;13:2467–8.

29 Augoustides JG. Cardiovascular consequences and considerations of coronavirus infection - perspectives for the cardiothoracic anesthesiologist and intensivist during the coronavirus crisis. J Cardiothorac Vasc Anesth 2020;34:1713–6.

30 Paternot A, Repessé X, Vieillard-Baron A. Rationale and description of right ventricle-protective ventilation in ARDS. Respir Care 2016;61:1391–6.

31 Repessé X, Charron C, Vieillard-Baron A. Acute respiratory distress syndrome: The heart side of the moon. Curr Opin Crit Care 2016;22:38–44.

32 Berglund JE, Haldén E, Jakobson S, et al. Echocardiographic analysis of cardiac function during high PEEP ventilation. Intensive Care Med 1994;20:174–80.

33 Crystal GJ, Pagel PS. Right ventricular perfusion: physiology and clinical implications. Anesthesiology 2018;128:202–18.

34 Guerracino F, Bertini P, Pinsky MR. Novel applications of bedside monitoring to plumb patient hemodynamic state and response to therapy. Minerva Anestesiol 2018;84:858–64.

35 Park JF, Banerjee S, Umar S. In the eye of the storm: The right ventricle in COVID-19. Pulm Circ 2020;10:2045894020936660.

36 Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: A multicentre prospective observational study. Lancet Respir Med 2020;8:1201–8.